Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation

Manoj N Obeyesekere, Siobhan Marie Lockwood, Phillip M Mottram, J F Alison

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Only 50 of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti-coagulation. Percutaneous strategies to treat AF, including pulmonary vein isolation with a curative intent or atrioventricular nodal ablation and implantation of a permanent pacemaker for palliative rate control, have not eliminated the need to manage thromboembolic risk. With the development of a percutaneous left atrial appendage (LAA) occlusion device (the WATCHMAN percutaneous left atrial appendage occluder - Atritech Inc., Plymouth, MN, USA) for thromboembolic protection in non-valvular AF a significant therapeutic option for select patients may be available. We present the first case performed in Australia (24 November 2009) and explore this new methodology.
Original languageEnglish
Pages (from-to)e15 - e19
Number of pages5
JournalInternal Medicine Journal
Issue number3
Publication statusPublished - 2012

Cite this